ImmunoGen’s (Nasdaq:IMGN) Elahere drug for treating platinum-resistant ovarian cancers in adults has been granted accelerated approval by the U.S. Food and Drug Administration (FDA). Following the news, IMGN stock jumped more than 10% in extended trading hours on Monday. The stock had already risen by more than 50% in the past six months.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The drug trial was conducted on 106 patients and was successful in meeting both the primary and secondary endpoints. Results show an overall response rate of 31.7% and a median duration of response of 6.9 months.
More specifically, the drug has been approved for patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, if they have received one to three prior regimens.
Full FDA approval for Elahere is dependent on the results of the Mirasol trial. Relevant data from that trial is expected in early 2023.
Is ImmunoGen a Good Stock to Buy?
With three Buy and two Hold ratings, ImmunoGen stock has a Moderate Buy consensus rating from analysts. On TipRanks, the average IMGN stock price forecast of $9.40 implies 63.19% upside potential to current levels.
